drugset
drugset / Trial / NCT06139341

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated

NCT06139341 ↗

Phase 1 Completed 32 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 765845 in healthy male Japanese subjects following intravenous administration of single rising doses.

Timeline

Start
2023-07-21
Primary completion
2023-12-17
Completion
2023-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 765845 Unknown — Intravenous

Indications

No indication recorded.